Clinical Trials Logo

Neoplasm, Residual clinical trials

View clinical trials related to Neoplasm, Residual.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06102889 Enrolling by invitation - Clinical trials for Pancreatic Adenocarcinoma

GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES

GUIDEMRD
Start date: March 2, 2024
Phase:
Study type: Observational

The overall objective of this study is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, we want to determine the association between disease-free survival (DFS) and ctDNA detection status after (1) curative-intended surgery and (2) adjuvant chemotherapy.